Author

Bruce A. Lefker

ORCID 0000-0003-0859-6956Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Bioinformatics· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 1 Organism:human· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1 Organism:non-human primate· 1 Assay:protein structure· 1 Approach:statistical model· 1

Frequent Co-Authors

Blake H. BalcombiD· 2 shared D. FearoniD· 2 shared Ed GriffeniD· 2 shared Haim Michael BarriD· 2 shared John D. ChoderaiD· 2 shared Noa Lahav· 2 shared Ralph P. RobinsoniD· 2 shared A. Kenneth MacLeodiD· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioinformatics

Blake H. BalcombORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BioinformaticsbioRxivPreprintJul 29, 2025

A Structure-Based Computational Pipeline for Broad-Spectrum Antiviral Discovery

Maria A. Castellanos, Alexander Matthew Payne, Jenke Scheen…·John D. Chodera

This paper introduces a computational pipeline for identifying broad-spectrum antivirals by analyzing viral sequences, predicting ligand poses, and scoring protein-ligand complexes, validated on SARS-CoV-2 and MERS-CoV datasets.

3 citations

humannon-human primate

𝕏 PostBluesky

Pharmacology & ToxicologybioRxivPreprintJun 16, 2025

Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor

Ed Griffen, D. Fearon, Briana Lynn McGovern…·Annette von Delft

This paper describes the optimization of a SARS-CoV-2 Mpro inhibitor to address genotoxic and metabolic liabilities, leading to improved in vivo efficacy and exposure.

5 citations

mouseexperimental assay

𝕏 PostBluesky